Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
941 to 960 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. | Front Genet | 2022 | 36479247 | PubTator, text mining | PubMed |
| The roles of lncRNA functions and regulatory mechanisms in the diagnosis and treatment of hepatocellular carcinoma. | Front Cell Dev Biol | 2022 | 36467404 | PubTator, text mining | PubMed |
| The m6A methylation profiles of immune cells in type 1 diabetes mellitus. | Front Immunol | 2022 | 36457997 | PubTator, text mining | PubMed |
| IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. | Mater Today Bio | 2022 | 36457846 | PubTator, text mining | PubMed |
| Coordinated transcriptional and post-transcriptional epigenetic regulation during skeletal muscle development and growth in pigs. | J Anim Sci Biotechnol | 2022 | 36457054 | PubTator, text mining | PubMed |
| A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma. | Oxid Med Cell Longev | 2022 | 36439693 | PubTator, text mining | PubMed |
| M6A regulator-mediated immune infiltration and methylation modification in hepatocellular carcinoma microenvironment and immunotherapy. | Front Pharmacol | 2022 | 36438800 | PubTator, text mining | PubMed |
| The role of RNA modification in the generation of acquired drug resistance in glioma. | Front Genet | 2022 | 36437944 | PubTator, text mining | PubMed |
BDE-47, -99, -209 and Their Ternary Mixture Disrupt Glucose and Lipid Metabolism of Hepg2 Cells at Dietary Relevant Concentrations: Mechanistic Insight through Integrated Transcriptomics and Proteomics Analysis. | Int J Mol Sci | 2022 | 36430946 | PubTator, text mining | PubMed |
| The Association of R-Loop Binding Proteins Subtypes with CIN Implicates Therapeutic Strategies in Colorectal Cancer. | Cancers (Basel) | 2022 | 36428700 | PubTator, text mining | PubMed |
| Latest updates on cellular and molecular biomarkers of gliomas. | Front Oncol | 2022 | 36425564 | PubTator, text mining | PubMed |
| CRIT: Identifying RNA-binding protein regulator in circRNA life cycle via non-negative matrix factorization. | Mol Ther Nucleic Acids | 2022 | 36420213 | PubTator, text mining | PubMed |
| Phosphorylation of T897 in the dimerization domain of Gemin5 modulates protein interactions and translation regulation. | Comput Struct Biotechnol J | 2022 | 36420152 | PubTator, text mining | PubMed |
| The genetic and biochemical determinants of mRNA degradation rates in mammals. | Genome Biol | 2022 | 36419176 | PubTator, text mining | PubMed |
| Analysis of cuproptosis in hepatocellular carcinoma using multi-omics reveals a comprehensive HCC landscape and the immune patterns of cuproptosis. | Front Oncol | 2022 | 36408192 | PubTator, text mining | PubMed |
| Editorial: Intra- and extra-environment and reproduction. | Front Cell Dev Biol | 2022 | 36407099 | PubTator, text mining | PubMed |
| Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression. | Front Immunol | 2022 | 36405712 | PubTator, text mining | PubMed |
| Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma. | Medicine (Baltimore) | 2022 | 36401386 | PubTator, text mining | PubMed |
| CircRNA AFF4 induced by KDM1A promotes osteogenic differentiation through FNDC5/Irisin pathway. | Mol Med | 2022 | 36401176 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. | Nucleic Acids Res | 2022 | 36399511 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=48